Doctors follow 500 kidney patients to unlock secrets of treatment success
NCT ID NCT06242327
Summary
This study aims to understand how well patients with a specific kidney disease called primary membranous nephropathy do when treated with antibody medications like rituximab in real-world settings. Researchers will follow 500 adult patients who have this disease with significant protein loss (nephrotic syndrome) to see who gets better, who doesn't, and why. By collecting long-term data from routine doctor visits, they hope to identify which patients respond best to these treatments and learn more about the disease's natural course.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITINGBergamo, BG, 24127, Italy
-
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
RECRUITINGRanica, BG, 24020, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.